Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. Its lead product candidate is navacaprant (NMRA-140), a once-daily oral kappa opioid receptor antagonist currently in Phase 3 clinical trials for major depressive disorder. The company also has NMRA-511 in Phase 1b trials for agitation associated with Alzheimer's disease dementia, and two M4 muscarinic receptor positive allosteric modulators (PAMs), NMRA-861 and NMRA-898, for schizophrenia and other neuropsychiatric conditions. Preclinical programs include NMRA-GCase for Parkinson's disease, NMRA-CK1d for amyotrophic lateral sclerosis, and NMRA-215, a brain-penetrant oral NLRP3 inhibitor for obesity.

Neumora Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol NMRA. Its trading currency is the US Dollar (USD), as the company is based in the United States. The exchange is one of the major US stock exchanges, providing liquidity and visibility for institutional and retail investors.

Neumora Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on developing novel therapies for brain diseases, including neuropsychiatric and neurodegenerative disorders. Biotechnology companies like Neumora use biological processes and research to create drugs, often targeting complex diseases with high unmet medical needs.

Neumora Therapeutics is headquartered in Watertown, Massachusetts, United States. The company was incorporated in 2019 and was formerly known as RBNC Therapeutics, Inc. before rebranding to Neumora Therapeutics in October 2021. Its operations are primarily based in the US, where it conducts its research and clinical development activities.

Neumora Therapeutics' pipeline includes several product candidates targeting brain diseases. The most advanced is navacaprant (NMRA-140), a kappa opioid receptor antagonist in Phase 3 trials for major depressive disorder. NMRA-511 is in Phase 1b for agitation in Alzheimer's disease. For schizophrenia and neuropsychiatric disorders, the company has two M4 muscarinic receptor positive allosteric modulators (PAMs): NMRA-861 and NMRA-898. Preclinical programs include NMRA-GCase for Parkinson's disease, NMRA-CK1d for amyotrophic lateral sclerosis, and NMRA-215, a brain-penetrant oral NLRP3 inhibitor for obesity.